Pfizer
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adult women who have both stress urinary incontinence (SUI) and obesity or overweight. Participants will be in the study for about 63 weeks
Inclusion Criteria: * Adult women aged 18 years or older * Body mass index (BMI) of 27 kg/m² or greater * Have a diagnosis of stress urinary incontinence * Willing and able to comply with study procedures Exclusion Criteria: * Have had urinary incontinence surgery * Have taken medications (prescribed or over-the counter) intended to promote weight loss within 90 days prior to randomization * Have recently received onabotulinumtoxin A (Botox) bladder injections or currently taking medications for urinary incontinence * History of acute or chronic pancreatitis * Personal or family history of…
Berobenatide administered by subcutaneous injection
Placebo administered by subcutaneous injection